FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146221483> ?p ?o ?g. }

• W2146221483 endingPage "689" @default.
• W2146221483 startingPage "685" @default.
• W2146221483 abstract "Background Angiogenesis has been reported as a parameter of potential prognostic value in solid tumours, as it may facilitate tumour growth and metastasis. One of the most important growth factors involved in angiogenesis is vascular endothelial growth factor (VEGF). Objectives To determine the predictive value of circulating VEGF levels in a cohort of patients with melanoma. Methods In a prospective cohort study, 324 patients with cutaneous melanoma at different clinical stages were investigated over 2 years (2002–04). VEGF was measured in plasma using enzyme‐linked immunosorbent assay. Two hundred and eight patients were able to be followed up for progression of their disease and for blood sample collection (mean ± SD follow‐up 13·4 ± 0·8 months). Data were compared with the extent of the disease and the clinical course. Results A significant increase in plasma VEGF levels was found in patients with melanoma compared with healthy controls, with statistically significant differences between patients in stages I, II and III vs. those in stage IV, but not between patients in stages I, II and III. When considering the 237 patients in stages I and II, no statistical correlation was found between plasma VEGF levels and tumour thickness. Baseline plasma VEGF levels were not significantly higher in patients who relapsed compared with nonprogressing patients. Among the 35 patients (two stage I, eight stage II and 25 stage III) who experienced a progression during follow‐up, an increase in plasma VEGF level to > 100 pg mL−1 was found in 20 (sensitivity 57·1%), while 38 of the 173 remaining nonprogressing patients demonstrated an increase in VEGF level, indicating a specificity of 78%. In addition, an increase in plasma VEGF level was found in 58 patients during follow‐up, of whom 20 showed evidence of progression, indicating a positive predictive value of 34·5%. However, among the 150 remaining patients who did not demonstrate any increase in plasma VEGF level during follow‐up, only 15 experienced a progression, indicating a negative predictive value of 90%. Conclusions Our data confirm that blood VEGF levels are significantly increased in patients with melanoma and, more interestingly, that the absence of plasma VEGF level increase during follow‐up appears to be associated with remission." @default.
• W2146221483 created "2016-06-24" @default.
• W2146221483 creator A5000608974 @default.
• W2146221483 creator A5002922004 @default.
• W2146221483 creator A5005689053 @default.
• W2146221483 creator A5024380579 @default.
• W2146221483 creator A5041710269 @default.
• W2146221483 creator A5044024585 @default.
• W2146221483 creator A5048514483 @default.
• W2146221483 creator A5069514820 @default.
• W2146221483 creator A5074447319 @default.
• W2146221483 date "2005-04-01" @default.
• W2146221483 modified "2023-10-15" @default.
• W2146221483 title "Circulating vascular endothelial growth factor in cutaneous malignant melanoma" @default.
• W2146221483 cites W1519942965 @default.
• W2146221483 cites W1828940258 @default.
• W2146221483 cites W1856388297 @default.
• W2146221483 cites W1863806376 @default.
• W2146221483 cites W1916387106 @default.
• W2146221483 cites W1918337600 @default.
• W2146221483 cites W1969208102 @default.
• W2146221483 cites W1974025321 @default.
• W2146221483 cites W1976123588 @default.
• W2146221483 cites W1993220471 @default.
• W2146221483 cites W2000208898 @default.
• W2146221483 cites W2008677826 @default.
• W2146221483 cites W2028825060 @default.
• W2146221483 cites W2031467322 @default.
• W2146221483 cites W2037761545 @default.
• W2146221483 cites W2042295867 @default.
• W2146221483 cites W2052139455 @default.
• W2146221483 cites W2064217869 @default.
• W2146221483 cites W2065874620 @default.
• W2146221483 cites W2067958384 @default.
• W2146221483 cites W2081762114 @default.
• W2146221483 cites W2088571368 @default.
• W2146221483 cites W2090877530 @default.
• W2146221483 cites W2101347382 @default.
• W2146221483 cites W2110076708 @default.
• W2146221483 cites W2142003423 @default.
• W2146221483 cites W2145159715 @default.
• W2146221483 cites W2156145383 @default.
• W2146221483 cites W2311972351 @default.
• W2146221483 cites W2321314469 @default.
• W2146221483 cites W2323491216 @default.
• W2146221483 cites W327131631 @default.
• W2146221483 doi "https://doi.org/10.1111/j.1365-2133.2005.06507.x" @default.
• W2146221483 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15840099" @default.
• W2146221483 hasPublicationYear "2005" @default.
• W2146221483 type Work @default.
• W2146221483 sameAs 2146221483 @default.
• W2146221483 citedByCount "37" @default.
• W2146221483 countsByYear W21462214832012 @default.
• W2146221483 countsByYear W21462214832014 @default.
• W2146221483 countsByYear W21462214832015 @default.
• W2146221483 countsByYear W21462214832016 @default.
• W2146221483 countsByYear W21462214832017 @default.
• W2146221483 countsByYear W21462214832019 @default.
• W2146221483 countsByYear W21462214832020 @default.
• W2146221483 countsByYear W21462214832021 @default.
• W2146221483 countsByYear W21462214832022 @default.
• W2146221483 crossrefType "journal-article" @default.
• W2146221483 hasAuthorship W2146221483A5000608974 @default.
• W2146221483 hasAuthorship W2146221483A5002922004 @default.
• W2146221483 hasAuthorship W2146221483A5005689053 @default.
• W2146221483 hasAuthorship W2146221483A5024380579 @default.
• W2146221483 hasAuthorship W2146221483A5041710269 @default.
• W2146221483 hasAuthorship W2146221483A5044024585 @default.
• W2146221483 hasAuthorship W2146221483A5048514483 @default.
• W2146221483 hasAuthorship W2146221483A5069514820 @default.
• W2146221483 hasAuthorship W2146221483A5074447319 @default.
• W2146221483 hasBestOaLocation W21462214831 @default.
• W2146221483 hasConcept C121608353 @default.
• W2146221483 hasConcept C126322002 @default.
• W2146221483 hasConcept C142724271 @default.
• W2146221483 hasConcept C143998085 @default.
• W2146221483 hasConcept C146357865 @default.
• W2146221483 hasConcept C151730666 @default.
• W2146221483 hasConcept C167734588 @default.
• W2146221483 hasConcept C188816634 @default.
• W2146221483 hasConcept C2777025900 @default.
• W2146221483 hasConcept C2777658100 @default.
• W2146221483 hasConcept C2779013556 @default.
• W2146221483 hasConcept C2780394083 @default.
• W2146221483 hasConcept C502942594 @default.
• W2146221483 hasConcept C71924100 @default.
• W2146221483 hasConcept C72563966 @default.
• W2146221483 hasConcept C86803240 @default.
• W2146221483 hasConcept C90924648 @default.
• W2146221483 hasConceptScore W2146221483C121608353 @default.
• W2146221483 hasConceptScore W2146221483C126322002 @default.
• W2146221483 hasConceptScore W2146221483C142724271 @default.
• W2146221483 hasConceptScore W2146221483C143998085 @default.
• W2146221483 hasConceptScore W2146221483C146357865 @default.
• W2146221483 hasConceptScore W2146221483C151730666 @default.
• W2146221483 hasConceptScore W2146221483C167734588 @default.
• W2146221483 hasConceptScore W2146221483C188816634 @default.
• W2146221483 hasConceptScore W2146221483C2777025900 @default.

• next